Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct formation in P450 reductase conditional null mice
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), formed during the cooking of foods, induces colon cancer in rodents. PhIP is metabolically activated by cytochromes P450 (P450s). To evaluate the role of hepatic P450s in the bioactivation of PhIP, we used Reductase Conditional Null (RCN) mice,...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
November 21, 2011
|
| In: |
Drug metabolism and disposition
Year: 2011, Jahrgang: 39, Heft: 12, Pages: 2169-2173 |
| ISSN: | 1521-009X |
| DOI: | 10.1124/dmd.111.041343 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1124/dmd.111.041343 Verlag, lizenzpflichtig, Volltext: https://dmd.aspetjournals.org/content/39/12/2169 
|
| Verfasserangaben: | Volker M. Arlt, Rajinder Singh, Marie Stiborová, Gonçalo Gamboa da Costa, Eva Frei, James D. Evans, Peter B. Farmer, C. Roland Wolf, Colin J. Henderson, David H. Phillips |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1796048828 | ||
| 003 | DE-627 | ||
| 005 | 20230428030502.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220318s2011 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1124/dmd.111.041343 |2 doi | |
| 035 | |a (DE-627)1796048828 | ||
| 035 | |a (DE-599)KXP1796048828 | ||
| 035 | |a (OCoLC)1341446227 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 32 |2 sdnb | ||
| 100 | 1 | |a Arlt, Volker M. |e VerfasserIn |0 (DE-588)121521281X |0 (DE-627)1726228339 |4 aut | |
| 245 | 1 | 0 | |a Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct formation in P450 reductase conditional null mice |c Volker M. Arlt, Rajinder Singh, Marie Stiborová, Gonçalo Gamboa da Costa, Eva Frei, James D. Evans, Peter B. Farmer, C. Roland Wolf, Colin J. Henderson, David H. Phillips |
| 264 | 1 | |c November 21, 2011 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.03.2022 | ||
| 520 | |a 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), formed during the cooking of foods, induces colon cancer in rodents. PhIP is metabolically activated by cytochromes P450 (P450s). To evaluate the role of hepatic P450s in the bioactivation of PhIP, we used Reductase Conditional Null (RCN) mice, in which cytochrome P450 oxidoreductase (POR), the unique electron donor to P450s, can be specifically deleted in hepatocytes by pretreatment with 3-methylcholanthrene (3-MC), resulting in the loss of essentially all hepatic P450 function. RCN mice were treated orally with 50 mg/kg b.wt. PhIP daily for 5 days, with and without 3-MC pretreatment. PhIP-DNA adducts (i.e., N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine [dG-C8-PhIP]), measured by liquid chromatography-tandem mass spectrometry, were highest in colon (1362 adducts/108 deoxynucleosides), whereas adduct levels in liver were ∼3.5-fold lower. Whereas no differences in PhIP-DNA adduct levels were found in livers with active POR versus inactivated POR, adduct levels were on average ∼2-fold lower in extrahepatic tissues of mice lacking hepatic POR. Hepatic microsomes from RCN mice with or without 3-MC pretreatment were also incubated with PhIP and DNA in vitro. PhIP-DNA adduct formation was ∼8-fold lower with hepatic microsomes from POR-inactivated mice than with those with active POR. Most of the hepatic microsomal activation of PhIP in vitro was attributable to CYP1A. Our results show that PhIP-DNA adduct formation in colon involves hepatic N-oxidation, circulation of activated metabolites via the bloodstream to extrahepatic tissues, and further activation, resulting in the formation of dG-C8-PhIP. Besides hepatic P450s, PhIP may be metabolically activated mainly by a non-P450 pathway in liver. | ||
| 700 | 1 | |a Singh, Rajinder |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stiborová, Marie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Costa, Gonçalo Gamboa da |e VerfasserIn |4 aut | |
| 700 | 1 | |a Frei, Eva |d 1950- |e VerfasserIn |0 (DE-588)112546450X |0 (DE-627)880025433 |0 (DE-576)483423068 |4 aut | |
| 700 | 1 | |a Evans, James D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Farmer, Peter B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wolf, C. Roland |e VerfasserIn |4 aut | |
| 700 | 1 | |a Henderson, Colin J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Phillips, David H. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism and disposition |d Bethesda, Md. : ASPET, 1973 |g 39(2011), 12, Seite 2169-2173 |h Online-Ressource |w (DE-627)306657198 |w (DE-600)1500213-5 |w (DE-576)309203163 |x 1521-009X |7 nnas |a Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct formation in P450 reductase conditional null mice |
| 773 | 1 | 8 | |g volume:39 |g year:2011 |g number:12 |g pages:2169-2173 |g extent:5 |a Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct formation in P450 reductase conditional null mice |
| 856 | 4 | 0 | |u https://doi.org/10.1124/dmd.111.041343 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://dmd.aspetjournals.org/content/39/12/2169 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220318 | ||
| 993 | |a Article | ||
| 994 | |a 2011 | ||
| 998 | |g 112546450X |a Frei, Eva |m 112546450X:Frei, Eva |d 140000 |e 140000PF112546450X |k 0/140000/ |p 5 | ||
| 999 | |a KXP-PPN1796048828 |e 4095396733 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1796048828","language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 18.03.2022"],"person":[{"display":"Arlt, Volker M.","roleDisplay":"VerfasserIn","role":"aut","family":"Arlt","given":"Volker M."},{"role":"aut","display":"Singh, Rajinder","roleDisplay":"VerfasserIn","given":"Rajinder","family":"Singh"},{"family":"Stiborová","given":"Marie","roleDisplay":"VerfasserIn","display":"Stiborová, Marie","role":"aut"},{"given":"Gonçalo Gamboa da","family":"Costa","role":"aut","display":"Costa, Gonçalo Gamboa da","roleDisplay":"VerfasserIn"},{"given":"Eva","family":"Frei","role":"aut","display":"Frei, Eva","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Evans, James D.","role":"aut","family":"Evans","given":"James D."},{"roleDisplay":"VerfasserIn","display":"Farmer, Peter B.","role":"aut","family":"Farmer","given":"Peter B."},{"role":"aut","display":"Wolf, C. Roland","roleDisplay":"VerfasserIn","given":"C. Roland","family":"Wolf"},{"display":"Henderson, Colin J.","roleDisplay":"VerfasserIn","role":"aut","family":"Henderson","given":"Colin J."},{"family":"Phillips","given":"David H.","roleDisplay":"VerfasserIn","display":"Phillips, David H.","role":"aut"}],"title":[{"title":"Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct formation in P450 reductase conditional null mice","title_sort":"Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct formation in P450 reductase conditional null mice"}],"relHost":[{"language":["eng"],"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"American Society for Pharmacology and Experimental Therapeutics"}],"recId":"306657198","type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct formation in P450 reductase conditional null miceDrug metabolism and disposition","note":["Gesehen am 23.06.2025"],"part":{"extent":"5","volume":"39","text":"39(2011), 12, Seite 2169-2173","pages":"2169-2173","issue":"12","year":"2011"},"pubHistory":["1.1973 -"],"title":[{"title_sort":"Drug metabolism and disposition","title":"Drug metabolism and disposition"}],"physDesc":[{"extent":"Online-Ressource"}],"name":{"displayForm":["American Society for Pharmacology and Experimental Therapeutics"]},"id":{"issn":["1521-009X"],"eki":["306657198"],"zdb":["1500213-5"]},"origin":[{"publisherPlace":"Bethesda, Md.","dateIssuedKey":"1973","publisher":"ASPET","dateIssuedDisp":"1973-"}]}],"physDesc":[{"extent":"5 S."}],"name":{"displayForm":["Volker M. Arlt, Rajinder Singh, Marie Stiborová, Gonçalo Gamboa da Costa, Eva Frei, James D. Evans, Peter B. Farmer, C. Roland Wolf, Colin J. Henderson, David H. Phillips"]},"id":{"doi":["10.1124/dmd.111.041343"],"eki":["1796048828"]},"origin":[{"dateIssuedDisp":"November 21, 2011","dateIssuedKey":"2011"}]} | ||
| SRT | |a ARLTVOLKEREFFECTOFHE2120 | ||